La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Meridian Bioscience Résultats passés
Passé contrôle des critères 1/6
Meridian Bioscience has been growing earnings at an average annual rate of 25.3%, while the Medical Equipment industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13% per year. Meridian Bioscience's return on equity is 11.5%, and it has net margins of 12.7%.
Informations clés
25.3%
Taux de croissance des bénéfices
24.7%
Taux de croissance du BPA
Medical Equipment Croissance de l'industrie | 8.9% |
Taux de croissance des recettes | 13.0% |
Rendement des fonds propres | 11.5% |
Marge nette | 12.7% |
Dernière mise à jour des bénéfices | 30 Sep 2022 |
Mises à jour récentes des performances passées
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Ventilation des recettes et des dépenses
Comment Meridian Bioscience gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Sep 22 | 333 | 42 | 88 | 24 |
30 Jun 22 | 344 | 43 | 90 | 24 |
31 Mar 22 | 339 | 62 | 86 | 24 |
31 Dec 21 | 313 | 60 | 80 | 24 |
30 Sep 21 | 318 | 71 | 76 | 24 |
30 Jun 21 | 306 | 71 | 76 | 25 |
31 Mar 21 | 327 | 87 | 76 | 25 |
31 Dec 20 | 299 | 70 | 74 | 25 |
30 Sep 20 | 254 | 46 | 71 | 24 |
30 Jun 20 | 240 | 44 | 68 | 22 |
31 Mar 20 | 204 | 21 | 64 | 20 |
31 Dec 19 | 197 | 19 | 61 | 19 |
30 Sep 19 | 201 | 24 | 62 | 18 |
30 Jun 19 | 203 | 26 | 62 | 16 |
31 Mar 19 | 207 | 27 | 64 | 16 |
31 Dec 18 | 213 | 26 | 68 | 16 |
30 Sep 18 | 214 | 24 | 70 | 17 |
30 Jun 18 | 210 | 24 | 69 | 18 |
31 Mar 18 | 209 | 18 | 68 | 17 |
31 Dec 17 | 206 | 22 | 66 | 17 |
30 Sep 17 | 201 | 22 | 63 | 16 |
30 Jun 17 | 198 | 21 | 63 | 15 |
31 Mar 17 | 199 | 30 | 63 | 15 |
31 Dec 16 | 195 | 30 | 61 | 14 |
30 Sep 16 | 196 | 32 | 59 | 14 |
30 Jun 16 | 195 | 35 | 58 | 13 |
31 Mar 16 | 192 | 36 | 55 | 13 |
Des revenus de qualité: VIVO has a large one-off loss of $21.2M impacting its last 12 months of financial results to 30th September, 2022.
Augmentation de la marge bénéficiaire: VIVO's current net profit margins (12.7%) are lower than last year (22.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: VIVO's earnings have grown significantly by 25.3% per year over the past 5 years.
Accélération de la croissance: VIVO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: VIVO had negative earnings growth (-40.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (3.7%).
Rendement des fonds propres
ROE élevé: VIVO's Return on Equity (11.5%) is considered low.